RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited ...
ROCKVILLE, Md.--(BUSINESS WIRE)-- OPIS, an IHS Markit (NYSE: INFO) company and the leading benchmark provider for emissions and carbon markets data, will launch today the world’s first comprehensive ...
The latest price target for Opus Genetics (NASDAQ:IRD) was reported by B. Riley Securities on December 10, 2025. The analyst firm set a price target for $9.00 expecting IRD to rise to within 12 months ...
The average one-year price target for Opus Genetics (NasdaqCM:IRD) has been revised to $7.87 / share. This is an increase of 13.45% from the prior estimate of $6.94 dated November 7, 2025. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback